Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation
This study is not yet recruiting. It focuses on PTSD and currently lists study information in the United States.
Key information made simple
What is this study testing?
This study is testing whether Dexmedetomidine (IV) 0.5 mcg/kg may be useful for children experiencing ptsd.
What would participation involve?
Participants may receive Dexmedetomidine (IV) 0.5 mcg/kg, complete questionnaires or follow-up assessments, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in the United States.
Who is it mainly for?
This study appears to be mainly for children with ptsd. Because it involves minors, a parent or guardian may need to be involved.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, what role parents or guardians have in the process.
Your next step
The official record does not clearly describe the visit format, so the practical details are best checked directly in the source. Participation appears to involve study activities and follow-up chosen by the research team. The main fit and exclusions are best confirmed in the eligibility section of the official record. The phase details are not clearly stated here.
Questions to ask before joining
- What are the exact eligibility criteria, and what could exclude someone?
- How many visits, assessments, or follow-ups are expected, and over what period?
- What risks, side effects, practical burdens, or alternatives should be understood first?
- Who should be contacted to confirm locations, timing, compensation, and next steps?
Things to check before joining
- Recruitment status
- Not Yet Recruiting
- Estimated enrollment
- 100
- Sponsor
- Stanford University
- Sponsor type
- University
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- PHASE2Usually explores whether the intervention may work, while continuing to monitor safety.
- Locations
- United States
- Age range
- Over 18 Years
- Official registry ID
- NCT07537894
- Official title
- Perioperative Dexmedetomidine to Reduce Post-procedure Grief Following Second-trimester Dilation and Evacuation
- Official source
- Official registry link
Want help reviewing this study?
For you
Taking part may give access to a new approach being evaluated.
It requires regular follow-up, often through questionnaires or interviews.
Not medical advice
Information from public sources. Are you the study sponsor? Contact us to update this page: hi@hopestage.com
Questions about this study
What is this study trying to understand?
Based on the public registry summary, this study is trying to understand: People seeking second-trimester dilation and evacuation (D\&E) procedures are often facing profoundly challenging circumstances, including desired pregnancies complicated by fetal anomalies or demise, serious maternal health conditions, or changes in financial or relationship. The study team can confirm the exact objective and what it means for you.
Does this study involve a medication?
This appears to be a medication / drug study involving Dexmedetomidine (IV) 0.5 mcg/kg, Placebo. The listed phase is PHASE2. Ask the study team what that means in practice for safety, monitoring, and criteria.
Who might this study be for?
This study may concern people with ptsd; age range: Over 18 Years. The criteria appear fairly specific, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Stanford University, which appears to be a university. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The registry indicates that this study has not started recruiting yet. You can check the planned start date and available contacts. The registry lists an estimated enrollment of 100 participants.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me
